Thoratec Corporation is a world leader in hemodynamic restoration therapy- developing products to treat cardiovascular disease. The company's product line includes the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 11,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.
Some of the preceding paragraphs, contain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934. These statements can be
identified by the words, "expects," "continues," "projects," "hopes,"
"believes," "could," and other similar words. Actual results, events or
performance could differ materially from these forward-looking statements
based on a variety of factors, many of which are beyond Thoratec's control.
Therefore, readers are cautioned not to put undue reliance on these
statements. Investors are cautioned that all such statements involve risk
and uncertainties. Forward- looking statements contained in this press
release should be considered in light of these factors, and those factors
discussed from time to time in Thoratec's public reports filed with the
Securities and Exchange Commission, such as those discussed under the
heading, "Risk Factors," in Thoratec's most recent annual report on Form
10-K and quarterly report on Form 10-Q. These forward-looking statements
speak only as of the date hereof. Thoratec undertakes no obligation to
publicly release the results of any revisions to these forward-looking
statements that may b
|SOURCE Thoratec Corporation|
Copyright©2007 PR Newswire.
All rights reserved